PiperJafrray's NIPT Survey Supports Average Risk Expansion Following Reimbursement
Investment bank PiperJaffray recently completed a survey of 600 obstetricians in the U.S. with results confirming market expansion in average risk non-invasive prenatal testing (NIPT) on the heals of broader commercial reimbursement. Its survey indicates only 33% of respondents routinely offer NIPT to average risk patients (vs. 79% to high risk patients), however most respondents cite private reimbursement as a barrier to routinely offering NIPT in the average risk population.
Following recent changes in the reimbursement policies of the major U.S. health insurance companies, we expect NIPT penetration to growth in the average risk population. The trend is expected to follow in Europe, where some public health reimbursement systems are reviewing inclusion of NIPT (such as U.K.), and general awareness of NIPT is increasing among OBGYNs, midwives, and expectant mothers.